Published by Josh White on 20th December 2017
(ShareCast News) - Specialty pharmaceutical company Midatech Pharma announced on Wednesday that its US subsidiary has initiated a Phase IV clinical trial at Dana-Farber/Brigham and Women's Cancer Center to study the effects of 'Gelclair' bio adherent oral gel on various aspects of oral mucositis (OM) - a common side effect experienced by patients undergoing stem cell transplant.